Breaking News, Collaborations & Alliances

Alcami Extends Workbench Laboratory Services Program

To support the ongoing manufacturing and development of ZILRETTA for Flexion Therapeutics

Alcami Corporation has announced the expanded deployment of its Extended Workbench laboratory services program to support the ongoing manufacturing and development of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension).    ZILRETTA is the first FDA approved product from Flexion Therapeutics. Flexion utilized Alcami’s Extended Workbench to support ZILRETTA from Phase 2 clinical trials through commercial launch and is using the program for the release and stabi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters